On January 19, 2026 Jecho (Tianjin) Biopharmaceutical Co., Ltd. (hereinafter referred to as "Jecho Bio") reported that its independently developed innovative drug, JLM019, has successfully completed dosing of the first subject in a clinical trial for advanced malignant tumors at Peking Union Medical College Hospital.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

JLM019 is a CD80/PD-1 dual-target Fc fusion protein with a unique bidirectional synergistic mechanism. With its precise targeting design, the drug is expected to overcome the limitations of existing immunotherapies, improve immunotherapy response rates, and delay the development of tumor cell resistance. As a result, it has the potential to significantly enhance immunotherapy and provide new treatment options and hope for survival for patients with advanced solid tumors and lymphomas.

This study is led by Professors Ba Yi and Han Xiaohong of Peking Union Medical College Hospital. The Phase 1 study is designed to evaluate the safety, tolerability, and preliminary efficacy of JLM019 injection in patients with advanced malignancies.

Jecho Bio remains committed to the development of innovative therapies to address unmet clinical needs and to promote the advancement of the biopharmaceutical industry. The company also looks forward to working closely with partners across the industry to accelerate the translation of innovative therapies into clinical practice and to jointly shape the future of the field.

(Press release, Jecho Laboratories, JAN 19, 2026, View Source [SID1234662130])